Hybrid Dose-fraction Radiotherapy for Metastatic Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
The combination of immune checkpoint inhibitors (ICI) and local ablative radiotherapy has
been demonstrated to be able to increase the survival of patients with metastatic
driven-genes negative non-small cell lung cancer. Various dose-fraction of radiotherapy could
exert different effects on the immune system. Ablative-dose could induce immunogenic cell
death through the activation of CD8+(Cluster of Differentiation) T cells. Low-dose could
modulate immune microenvironment from immunosuppression to inflammatory anti-tumor phenotype.
This trial is designed to validation the safety and primary efficacy of the combination of
hybrid dose-fraction radiotherapy with ICI for metastatic driven-genes negative non-small
cell lung cancer patients.